Published in Nature on March 12, 1992
HIV-1 Vaccine Test in Uninfected Adult Volunteers | NCT00045838
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 3.49
Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. Microbiol Mol Biol Rev (2005) 3.06
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol (1998) 2.82
Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A (1994) 2.58
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A (1996) 2.02
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A (1998) 1.88
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol (2007) 1.87
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Human herpesvirus 8 glycoprotein B (gB), gH, and gL can mediate cell fusion. J Virol (2002) 1.85
DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol (1995) 1.83
Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol (1998) 1.82
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol (2001) 1.81
Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol (1996) 1.80
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med (1997) 1.53
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology (1996) 1.52
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.51
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology (1995) 1.46
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact (2011) 1.45
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.43
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 1.37
DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol (1998) 1.34
DNA vaccination against persistent viral infection. J Virol (1995) 1.33
Molecular genetics of the cutaneous basement membrane zone. Perspectives on epidermolysis bullosa and other blistering skin diseases. J Clin Invest (1992) 1.29
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther (2003) 1.28
DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A (1997) 1.27
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol (1995) 1.25
Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med (1999) 1.22
Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A (1995) 1.21
The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine (2008) 1.20
Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19
DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
The future of human DNA vaccines. J Biotechnol (2012) 1.18
In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm (2011) 1.17
Immunological methods for detection and identification of infectious disease and biological warfare agents. Clin Diagn Lab Immunol (2003) 1.16
Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J Virol (2002) 1.15
Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther (2009) 1.15
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun (2004) 1.09
Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest (1996) 1.08
Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect Immun (2000) 1.08
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci (2006) 1.05
Dominant dystrophic epidermolysis bullosa: identification of a Gly-->Ser substitution in the triple-helical domain of type VII collagen. Proc Natl Acad Sci U S A (1994) 1.05
The promise of nucleic acid vaccines. Gene Ther (2000) 1.05
Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J (2012) 1.04
Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci U S A (2000) 1.04
Dendritic cells can initiate protective immune responses against malaria. Infect Immun (2001) 1.04
TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology (2004) 1.04
Stimulation of protective CD8+ T lymphocytes by vaccination with nonliving bacteria. Proc Natl Acad Sci U S A (1995) 1.04
On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect Immun (2003) 1.02
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
Physical characterization of the "immunosignaturing effect". Mol Cell Proteomics (2012) 1.00
Screening of protective antigens of Japanese encephalitis virus by DNA immunization: a comparative study with conventional viral vaccines. J Virol (1999) 1.00
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine (2010) 1.00
C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest (2000) 1.00
Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One (2011) 0.99
Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc Natl Acad Sci U S A (1998) 0.99
Designing a vaccine for tuberculosis. BMJ (1996) 0.98
Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One (2012) 0.96
Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J Virol (1995) 0.95
CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun (2009) 0.95
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J Immunol Methods (1998) 0.95
Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect Immun (1996) 0.95
Papilloma formation in human foreskin xenografts after inoculation of human papillomavirus type 16 DNA. J Virol (1995) 0.95
Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol (2008) 0.95
A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J Virol (2005) 0.95
Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother (2013) 0.94
Vaccines to prevent leishmaniasis. Clin Transl Immunology (2014) 0.94
Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92
DNA vaccines for targeting bacterial infections. Expert Rev Vaccines (2010) 0.92
Transcriptomic basis for an antiserum against Micrurus corallinus (coral snake) venom. BMC Genomics (2009) 0.92
Premature termination codons on both alleles of the type VII collagen gene (COL7A1) in three brothers with recessive dystrophic epidermolysis bullosa. J Clin Invest (1995) 0.92
Endothelial cells present antigens in vivo. BMC Immunol (2004) 0.92
Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults. Mol Ther (2011) 0.92
What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother (2012) 0.92
DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc. World J Gastroenterol (2000) 0.92
Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine. Drug Des Devel Ther (2013) 0.91
Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol (1994) 0.91
DNA vaccination favours memory rather than effector B cell responses. Clin Exp Immunol (1999) 0.91
Gene therapy for infectious diseases. Clin Microbiol Rev (1998) 0.91
Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon. Proc Natl Acad Sci U S A (1982) 6.22
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature (1995) 3.27
Overview of adult health measures fielded in Rand's health insurance study. Med Care (1979) 3.20
Genetic evidence that an activation domain of GAL4 does not require acidity and may form a beta sheet. Cell (1993) 3.05
The acidic activation domains of the GCN4 and GAL4 proteins are not alpha helical but form beta sheets. Cell (1993) 2.80
Analysis of the Kluyveromyces lactis positive regulatory gene LAC9 reveals functional homology to, but sequence divergence from, the Saccharomyces cerevisiae GAL4 gene. Nucleic Acids Res (1986) 2.76
Interaction of positive and negative regulatory proteins in the galactose regulon of yeast. Cell (1987) 2.75
Release of proteins and peptides from fusion proteins using a recombinant plant virus proteinase. Anal Biochem (1994) 2.71
The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. Mol Cell (2001) 2.45
GAL4 interacts with TATA-binding protein and coactivators. Mol Cell Biol (1995) 2.10
Nondissociation of GAL4 and GAL80 in vivo after galactose induction. Science (1992) 1.98
Alterations in a yeast protein resembling HIV Tat-binding protein relieve requirement for an acidic activation domain in GAL4. Nature (1992) 1.94
The 19S regulatory complex of the proteasome functions independently of proteolysis in nucleotide excision repair. Mol Cell (1999) 1.92
Protection against mycoplasma infection using expression-library immunization. Nature (1995) 1.88
A highly conserved ATPase protein as a mediator between acidic activation domains and the TATA-binding protein. Nature (1995) 1.83
Genome-directed primers for selective labeling of bacterial transcripts for DNA microarray analysis. Nat Biotechnol (2000) 1.83
Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci U S A (1991) 1.80
Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med (1996) 1.79
Linear expression elements: a rapid, in vivo, method to screen for gene functions. Nat Biotechnol (1999) 1.76
Subcellular localization, stoichiometry, and protein levels of 26 S proteasome subunits in yeast. J Biol Chem (1999) 1.69
Functional domains of the yeast regulatory protein GAL4. Proc Natl Acad Sci U S A (1986) 1.64
Evidence for two modes of cooperative DNA binding in vivo that do not involve direct protein-protein interactions. Curr Biol (1998) 1.60
Altering DNA-binding specificity of GAL4 requires sequences adjacent to the zinc finger. Nature (1989) 1.57
Biolistic nuclear transformation of Saccharomyces cerevisiae and other fungi. Curr Genet (1990) 1.54
Analysis of the galactose signal transduction pathway in Saccharomyces cerevisiae: interaction between Gal3p and Gal80p. Mol Cell Biol (1996) 1.51
Hookworms in the Americas: An alternative to trans-Pacific contact. Parasitol Today (1996) 1.49
How do "Zn2 cys6" proteins distinguish between similar upstream activation sites? Comparison of the DNA-binding specificity of the GAL4 protein in vitro and in vivo. J Biol Chem (1993) 1.45
The 19S complex of the proteasome regulates nucleotide excision repair in yeast. Genes Dev (2001) 1.36
Crystal structure of a conserved protease that binds DNA: the bleomycin hydrolase, Gal6. Science (1995) 1.34
GAL4 of Saccharomyces cerevisiae activates the lactose-galactose regulon of Kluyveromyces lactis and creates a new phenotype: glucose repression of the regulon. Mol Cell Biol (1987) 1.33
Isolation and characterization of SUG2. A novel ATPase family component of the yeast 26 S proteasome. J Biol Chem (1996) 1.31
Evidence that Gal11 protein is a target of the Gal4 activation domain in the mediator. Biochemistry (2001) 1.27
GAL4 mutations that separate the transcriptional activation and GAL80-interactive functions of the yeast GAL4 protein. Genetics (1990) 1.19
Interaction between transcriptional activator protein LAC9 and negative regulatory protein GAL80. Mol Cell Biol (1989) 1.19
Manipulations of endosperm balance number overcome crossing barriers between diploid solanum species. Science (1982) 1.16
Biological features of genetic immunization. Vaccine (1997) 1.14
Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther (1994) 1.11
Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc (1999) 1.06
The Gal4 activation domain binds Sug2 protein, a proteasome component, in vivo and in vitro. J Biol Chem (2001) 1.02
Evidence that proteolysis of Gal4 cannot explain the transcriptional effects of proteasome ATPase mutations. J Biol Chem (2001) 1.02
Quantitative analysis of the immunopotency of genetically transfected dendritic cells. Proc Natl Acad Sci U S A (1998) 0.99
A single GAL4 dimer can maximally activate transcription under physiological conditions. Proc Natl Acad Sci U S A (1995) 0.98
New chemistry for the study of multiprotein complexes: the six-histidine tag as a receptor for a protein crosslinking reagent. Chem Biol (1996) 0.97
The DNA binding and activation domains of Gal4p are sufficient for conveying its regulatory signals. Mol Cell Biol (1997) 0.97
Transcription of multiple copies of the yeast GAL7 gene is limited by specific factors in addition to GAL4. Mol Gen Genet (1987) 0.97
Semaphorin III can repulse and inhibit adult sensory afferents in vivo. Nat Med (1997) 0.94
Alterations in the GAL4 DNA-binding domain can affect transcriptional activation independent of DNA binding. J Biol Chem (1998) 0.93
Are all DNA binding and transcription regulation by an activator physiologically relevant? Mol Cell Biol (2001) 0.92
Production of monoclonal antibodies by genetic immunization. Biotechniques (1994) 0.89
Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses. DNA Cell Biol (1999) 0.88
The unusual active site of Gal6/bleomycin hydrolase can act as a carboxypeptidase, aminopeptidase, and peptide ligase. Cell (1998) 0.88
Yeast bleomycin hydrolase is a DNA-binding cysteine protease. Identification, purification, biochemical characterization. J Biol Chem (1994) 0.86
The cysteine-peptidase bleomycin hydrolase is a member of the galactose regulon in yeast. J Biol Chem (1997) 0.85
Potent peptide inhibitors of smooth muscle myosin light chain kinase: mapping of the pseudosubstrate and calmodulin binding domains. Arch Biochem Biophys (1990) 0.85
A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses. Vaccine (2001) 0.85
Crystal structure of human bleomycin hydrolase, a self-compartmentalizing cysteine protease. Structure (1999) 0.84
Use of carprofen for the treatment of pain and inflammation in dogs. J Am Vet Med Assoc (1997) 0.84
Protection against Mycoplasma pulmonis infection by genetic vaccination. DNA Cell Biol (1995) 0.84
Controlled gene gun delivery and expression of DNA within the cornea. Biotechniques (1997) 0.84
Rectal ganglioneuroma in a dog. J Am Anim Hosp Assoc (1999) 0.82
Slow-acting, disease-modifying osteoarthritis agents. Vet Clin North Am Small Anim Pract (1997) 0.82
Application of TEV Protease in Protein Production. Methods Mol Med (1998) 0.82
Pathogen-derived resistance to viral infection using a negative regulatory molecule. Virology (1987) 0.82
Identification of a phylogenetically conserved Sug1 CAD family member that is differentially expressed in the mouse nervous system. J Neurobiol (1997) 0.82
Comparison of stance time and velocity as control variables in force plate analysis of dogs. Am J Vet Res (1999) 0.80
Selective chemical inactivation of AAA proteins reveals distinct functions of proteasomal ATPases. Chem Biol (2001) 0.80
CADp44: a novel regulatory subunit of the 26S proteasome and the mammalian homolog of yeast Sug2p. Gene (1996) 0.80
Chylothorax associated with constrictive pericarditis in a dog. J Am Vet Med Assoc (1995) 0.78
Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter. Gene Ther (2001) 0.78
Income group differences in relationships among survey measures of physical and mental health. Health Serv Res (1976) 0.78
Affinity purification of proteins binding to GST fusion proteins. Curr Protoc Mol Biol (2001) 0.77
Induction of Th2-directed immune responses by IL-4-transduced dendritic cells in mice. Vaccine (2000) 0.77
Variation of lung density corrections in a typical patient population. Med Dosim (1989) 0.76
Alterations in a yeast protein resembling HIV Tat-binding protein relieve requirement for an acidic activation domain in GAL4. Nature (1993) 0.76
Evaluation of a method for experimental induction of osteoarthritis of the hip joints in dogs. Am J Vet Res (2000) 0.76
Synaptic and neurotransmitter regulation of activity in mammalian hypothalamic magnocellular neurosecretory cells. Prog Brain Res (1992) 0.76
The nucleic acid binding activity of bleomycin hydrolase is involved in bleomycin detoxification. Mol Cell Biol (1998) 0.76
The clinical, cerebrospinal fluid, and histopathologic effects of epidural ketorolac in dogs. Vet Surg (2000) 0.76
Immune responses in baboons vaccinated with HIV-2 genetic expression libraries. J Med Primatol (2002) 0.75
Controlled cross circulation in dogs: effects on donor hemodynamics. Vet Surg (1996) 0.75
The dangers of 'splicing and dicing': on the use of chimeric transcriptional activators in vitro. Chem Biol (1995) 0.75
Pantarsal arthrodesis in dogs and a cat: 11 cases (1983-1991). J Am Vet Med Assoc (1993) 0.75
Eukaryotic gene regulation: simple vs complex models. SAAS Bull Biochem Biotechnol (1991) 0.75
Naivete and need for affection among pedophiles. J Clin Psychol (1992) 0.75
A cognitive approach to validation of the fixated-regressed typology of child molesters. J Clin Psychol (1997) 0.75
Differences between human figure drawings of child molesters and control groups. J Clin Psychol (1986) 0.75
Minimally displaced tibial tuberosity avulsion fracture in nine skeletally immature large breed dogs. Vet Comp Orthop Traumatol (2012) 0.75
Quantitative autoradiography of parathyroid glands in rats with carbon-14-labeled amino acids. J Nucl Med (1987) 0.75
The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Intern Med (1999) 0.75
The preventive dental program in Saskatchewan. Can Dent Hyg (1967) 0.75
The genetics of triploid formation and its relationship to endosperm balance number in potato. Genome (1995) 0.75
Genetic control of Endosperm Balance Number (EBN) in the Solanaceae based on trisomic and mutation analysis. Genome (1996) 0.75
Effects of a prostaglandin E1 analogue, misoprostol, on renal function in dogs receiving nephrotoxic doses of gentamicin. Am J Vet Res (1998) 0.75